AWM Investment Company Inc. acquired a new stake in OPKO Health, Inc. (NASDAQ:OPK - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 2,110,000 shares of the biotechnology company's stock, valued at approximately $3,165,000. AWM Investment Company Inc. owned about 0.28% of OPKO Health as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently bought and sold shares of OPK. Zacks Investment Management acquired a new position in shares of OPKO Health during the fourth quarter valued at $27,000. StoneX Group Inc. bought a new stake in OPKO Health during the 4th quarter worth about $27,000. Apella Capital LLC acquired a new position in OPKO Health during the 1st quarter valued at about $34,000. Cibc World Markets Corp bought a new position in shares of OPKO Health in the 4th quarter valued at about $34,000. Finally, Diversify Advisory Services LLC bought a new position in shares of OPKO Health in the 2nd quarter valued at about $37,000. Institutional investors and hedge funds own 64.63% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on OPK shares. Barrington Research cut OPKO Health from an "outperform" rating to a "market perform" rating in a research note on Wednesday, April 29th. Weiss Ratings reissued a "sell (d-)" rating on shares of OPKO Health in a research note on Thursday, August 13th. HC Wainwright restated a "buy" rating on shares of OPKO Health in a report on Wednesday, July 29th. Finally, Wall Street Zen upgraded OPKO Health from a "sell" rating to a "hold" rating in a report on Saturday, June 6th. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $1.55.
Read Our Latest Stock Analysis on OPK
OPKO Health Stock Performance
NASDAQ OPK opened at $1.49 on Wednesday. The firm has a 50-day moving average of $1.38 and a 200-day moving average of $1.28. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.93 and a current ratio of 3.35. The stock has a market cap of $1.11 billion, a PE ratio of -16.56 and a beta of 1.51. OPKO Health, Inc. has a 52-week low of $0.98 and a 52-week high of $1.73.
OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings results on Monday, July 27th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.07. OPKO Health had a negative return on equity of 5.88% and a negative net margin of 12.40%.The business had revenue of $163.58 million for the quarter, compared to the consensus estimate of $131.23 million. During the same quarter in the prior year, the business posted ($0.19) earnings per share. The firm's quarterly revenue was up 4.3% compared to the same quarter last year. On average, sell-side analysts anticipate that OPKO Health, Inc. will post -0.23 EPS for the current year.
OPKO Health Profile
(
Free Report)
OPKO Health, Inc NASDAQ: OPK is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.
In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.
Read More
Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OPKO Health, Inc. (NASDAQ:OPK - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider OPKO Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OPKO Health wasn't on the list.
While OPKO Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
